These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 7762909

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 4. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy.
    Brennan DC, Garlock KA, Lippmann BA, Buller RS, Gaudreault-Keener M, Lowell JA, Miller SB, Shenoy S, Howard TK, Storch GA.
    J Am Soc Nephrol; 1997 Jan; 8(1):118-25. PubMed ID: 9013456
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy.
    Morales E, Andrés A, González E, Herrero JC, Muñoz MA, Ortiz M, Espejo B, Lumbreras C, Morales JM, Aguado JM.
    Transplant Proc; 2002 Feb; 34(1):73-4. PubMed ID: 11959191
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Feb; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 9. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT, Berger SP, Vossen AC, van der Blij-de Brouwer CS, Press RR, de Fijter JW, Claas EC, Kroes AC.
    Transplantation; 2010 Feb 15; 89(3):320-6. PubMed ID: 20145523
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N, Holman MJ, Yang HC.
    Clin Transplant; 1997 Dec 15; 11(6):633-9. PubMed ID: 9408699
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E, Suter F, Baruzzo S, Perani V, Moioli F, Remuzzi G.
    Clin Transplant; 1996 Dec 15; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [Abstract] [Full Text] [Related]

  • 13. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 14. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.
    Taber DJ, Ashcraft E, Baillie GM, Berkman S, Rogers J, Baliga PK, Rajagopalan PR, Lin A, Emovon O, Afzal F, Chavin KD.
    Transpl Infect Dis; 2004 Sep 15; 6(3):101-9. PubMed ID: 15569225
    [Abstract] [Full Text] [Related]

  • 15. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
    Winston DJ, Wirin D, Shaked A, Busuttil RW.
    Lancet; 1995 Jul 08; 346(8967):69-74. PubMed ID: 7603215
    [Abstract] [Full Text] [Related]

  • 16. Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients.
    Brennan DC, Garlock KA, Lippmann BJ, Buller RS, Gaudreault-Keener M, Lowell JA, Miller SB, Shenoy S, Howard TK, Storch GA.
    Transplant Proc; 1997 Jul 08; 29(1-2):809-11. PubMed ID: 9123536
    [No Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S, Mayo C, McCullough C, Jendrisak M, Woodle S, Marsh W, Bailey T.
    Transplant Proc; 1993 Feb 08; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract] [Full Text] [Related]

  • 18. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 19. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts.
    Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV.
    Liver Transpl; 2008 Feb 27; 14(2):240-4. PubMed ID: 18236404
    [Abstract] [Full Text] [Related]

  • 20. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation.
    Posadas Salas MA, Taber DJ, Chua E, Pilch N, Chavin K, Thomas B.
    Transpl Infect Dis; 2013 Dec 27; 15(6):551-8. PubMed ID: 24010993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.